2014’s biggest investments: Cell Medica £50m

Second in our list is this Imperial Innovations-led funding round for cellular immunotherapy company

Edged into second place in our list this creator of treatments for cancer and infectious diseases closed a £50m Series B round led by Imperial Innovations in November last year, with additional funding from Invesco Asset Management and Woodford Investment Management. Co-founded by Imperial Innovations, Cell Medica said the latest investment will help the company further develop its cellular immunotherapy products, with its lead oncology product already undergoing clinical trials.

Comments

(will not be published)